TWI PHARMACEUTICALS, INC. – Trademark Portfolio
Entity Type: 03
TWI PHARMACEUTICALS, INC. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 3 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 4 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include TWI and NAPRELAN. The owner is based in PARAMUS, NJ.
115 WEST CENTURY ROAD, SUITE 135
PARAMUS, NJ 07652
Showing of trademarks Trademarks
Trademark Classifications
TWI PHARMACEUTICALS, INC.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does TWI PHARMACEUTICALS, INC. have?
TWI PHARMACEUTICALS, INC. has 4 U.S. trademarks filed with the USPTO. Of these, 4 registered.
What trademark classes does TWI PHARMACEUTICALS, INC. file in?
TWI PHARMACEUTICALS, INC. files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business), Class 42 (Computer & Scientific), Class 40 (Treatment & Processing). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are TWI PHARMACEUTICALS, INC.'s most well-known trademarks?
TWI PHARMACEUTICALS, INC.'s registered trademark portfolio includes well-known marks such as TWI and NAPRELAN. These are among 4 currently registered trademarks in the portfolio.
What is TWI PHARMACEUTICALS, INC.'s trademark registration success rate?
TWI PHARMACEUTICALS, INC. has a 100% trademark registration rate, with 4 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.